Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY) will present at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. CEO Shalabh Gupta will share insights into the company's late-stage program targeting hyperphosphatemia and an early-stage program addressing mitochondrial dysfunction diseases. Investors can schedule one-on-one meetings through Roth representatives. The firm is advancing its lead drug, Renazorb, a phosphate-binding agent, and UNI-494, a new chemical entity for acute kidney injury treatment. For inquiries, investors can contact ir@unicycive.com.

News Market Reaction – UNCY

+1.39%

+1.39% Session move

In the trading session that priced this news, UNCY gained 1.39%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction

LOS ALTOS, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chairman and Chief Executive Officer of Unicycive, will present a corporate overview and meet with investors at the upcoming Roth Inaugural Healthcare Opportunities Conference taking place October 6, 2022 in New York City.

For investors interested in scheduling a one-on-one meeting with Unicycive management, please contact your Roth representative. For questions or further information about Unicycive, please contact Anne Marie Fields of Stern IR at 212-362-1200 or submit your request to ir@unicycive.com.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.

Investor Contact:

ir@unicycive.com
(650) 900-5470

Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
212-362-1200

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When is Unicycive Therapeutics presenting at the Roth Conference?

Unicycive Therapeutics will present on October 6, 2022.

Who is the CEO of Unicycive Therapeutics?

The CEO of Unicycive Therapeutics is Shalabh Gupta, M.D.

What is Renazorb developed by Unicycive Therapeutics?

Renazorb is a novel phosphate-binding agent for treating hyperphosphatemia.

What is UNI-494 in relation to Unicycive Therapeutics?

UNI-494 is a patent-protected new chemical entity in late preclinical development for acute kidney injury.

How can investors contact Unicycive Therapeutics?

Investors can contact Unicycive at ir@unicycive.com for inquiries.